Octagon Capital Advisors LP Rapt Therapeutics, Inc. Transaction History
Octagon Capital Advisors LP
- $639 Million
- Q1 2024
A detailed history of Octagon Capital Advisors LP transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 292,000 shares of RAPT stock, worth $890,600. This represents 0.41% of its overall portfolio holdings.
Number of Shares
292,000
Previous 292,000
-0.0%
Holding current value
$890,600
Previous $7.26 Million
63.86%
% of portfolio
0.41%
Previous 1.21%
Shares
1 transactions
Others Institutions Holding RAPT
# of Institutions
148Shares Held
29.2MCall Options Held
709KPut Options Held
1.06M-
Column Group LLC San Francisco, CA2.68MShares$8.18 Million15.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$7.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$7.54 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.03MShares$6.19 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$5.81 Million0.0% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $90.5M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...